Advertisement

UTHR

United Therapeutics Corporation

Healthcare · USD

Set alert

Price alert · UTHR

All alert types
598.72 USD +5.18 +0.87%
As of Oct 30, 2026 Extended hours 598.72 0.00%
Bid
598.41 × 1
Ask
599.04 × 1
593.57 Day range 609.99
437.33 52-week range 598.72
YTD
+22.88%
1 year
+32.01%
Open
600.00
Prev close
593.54
Mkt cap
25.68B
Vol
518.24K
Avg vol
717.53K
EPS
27.92
P/E
21.44
Div yield
0.00%
More statistics
Low
593.57
High
609.99
Forward P/E
17.67
Beta
0.49
Short ratio
2.42
Inst. own
100.39%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
525.55
200-d avg
530.92
1y target
670.93

5D chart

Chart tools
Interval
UTHR five-day price chart581.9588.9595.9603.0610.0Oct 26Oct 28Oct 29Oct 30

Key statistics

Market cap
25.68B
Enterprise value
22.80B
Trailing P/E
21.44
Forward P/E
17.67
PEG ratio
2.22
Price / sales
8.14
Price / book
3.99
EPS (TTM)
27.92
Beta
0.49
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
41.56%
Revenue (TTM)
3.15B
Revenue growth
-1.90%
Free cash flow
557.14M
Total cash
2.66B
Total debt
0
Return on equity
19.31%
Shares outstanding
42.89M
Short % of float
6.69%
50-day average
525.55
200-day average
530.92

Analyst view

Consensus: buy

Buy
Price target (mean) 670.93 +12.1% upside
Target (low)
368.00
Target (mean)
670.93
Target (high)
850.00
Ratings (0m) 15 11 buy · 3 hold · 1 sell
  • Strong buy3
  • Buy8
  • Hold3
  • Sell1
  • Strong sell0

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 6.34.

Earnings history

Financials — quick view

All financials
UTHR Revenue — quarterly 783.30M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
UTHR Net income — quarterly 333.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
UTHR EPS — quarterly 7.82
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

UTHR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 20266.01———
Aug 5, 2026Jun 30, 20266.867.27+0.41+5.98%
May 6, 2026Mar 31, 20267.005.82-1.18-16.86%
Feb 25, 2026Dec 31, 20257.137.70+0.57+7.99%
Oct 29, 2025Sep 30, 20256.897.16+0.27+3.92%
Jul 30, 2025Jun 30, 20257.296.41-0.88-12.07%

Upgrades / downgrades

UTHR analyst upgrades and downgrades
DateFirmActionFromTo
Oct 28, 2026JP MorganmainOverweightOverweight
Oct 22, 2026RBC CapitalmainOutperformOutperform
Oct 19, 2026Leerink PartnersmainOutperformOutperform
Oct 8, 2026RBC CapitalmainOutperformOutperform
Oct 7, 2026Morgan StanleymainEqual-WeightEqual-Weight
Oct 1, 2026BTIGupNeutralBuy

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
unither.com

News

Your note

Sign in to keep a note on UTHR — it syncs with the Stock Master app.

Insider holders

UTHR insider holders
InsiderRelationLatest transactionDateShares held
BENKOWITZ MICHAELPresidentConversion of Exercise of derivative securityMar 12, 20260
CAUSEY CHRISTOPHERDirectorSaleMar 29, 20264,190
EDGEMOND JAMES C.Chief Financial OfficerSaleJun 21, 202618,876
GILTNER RICHARD ADirectorConversion of Exercise of derivative securityJul 8, 202621,884
KURZWEIL RAYMOND CDirectorConversion of Exercise of derivative securityJul 8, 202613,320
MAHON PAUL AGeneral CounselSaleSep 30, 202645,172

Institution ownership

UTHR institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.34%5,294,5293.17BJun 29, 2026
Avoro Capital Advisors LLC6.48%2,777,7771.66BJun 29, 2026
Vanguard Portfolio Management LLC4.48%1,919,4291.15BJun 29, 2026
Vanguard Capital Management LLC4.47%1,918,2561.15BJun 29, 2026
State Street Corporation4.43%1,898,0641.14BJun 29, 2026
Renaissance Technologies, LLC3.98%1,708,7391.02BJun 29, 2026

Fund ownership

UTHR fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%1,527,799914.72MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.14%1,347,720806.91MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.27%973,490582.85MJun 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund1.68%719,385430.71MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.13%486,555291.31MJun 29, 2026
iShares Trust-iShares Biotechnology ETF0.75%323,432193.65MSep 29, 2026
Advertisement